Patents by Inventor Jiri Kasparec

Jiri Kasparec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10064854
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: September 4, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Neil W. Johnson, Jiri Kasparec
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20180000805
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 4, 2018
    Inventors: Neil W. Johnson, Jiri Kasparec
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 9795597
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: October 24, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Neil W. Johnson, Jiri Kasparec
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20170029412
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20160220547
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Inventors: Neil W. JOHNSON, Jiri Kasparec
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 9346840
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: May 24, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian, William Henry Miller, Dominic Suarez
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160102083
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 14, 2016
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20140371176
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Inventors: Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 8853408
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: October 7, 2014
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Neil W. Johnson, Jiri Kasparec
  • PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK
    Publication number: 20140155410
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R11, R12, R13, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Jerry Leroy Adams, Thomas H. Faitg, Neil W. Johnson, Jiri Kasparec, Hong Lin, Mark Mellinger, Xin Peng, Ren Xie
  • PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK
    Publication number: 20140107131
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R11, R12, R13, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
    Type: Application
    Filed: October 7, 2013
    Publication date: April 17, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Jerry Leroy ADAMS, Thomas H. FAITG, Neil W. JOHNSON, Jiri KASPAREC, Hong LIN, Mark MELLINGER, Xin PENG, Ren XIE
  • CYCLOPROPYLAMINES AS LSD1 INHIBITORS
    Publication number: 20140018393
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Application
    Filed: March 26, 2012
    Publication date: January 16, 2014
    Inventors: Neil W. Johnson, Jiri Kasparec
  • 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
    Patent number: 8058282
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: November 15, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK
    Publication number: 20110269774
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R11, R12, R13, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
    Type: Application
    Filed: April 29, 2011
    Publication date: November 3, 2011
    Inventors: Jerry ADAMS, Thomas Faitg, Neil Johnson, Jiri Kasparec, Hong Lin, Mark Mellinger, Xin Peng, Ren Xie
  • 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY
    Publication number: 20110046109
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: August 19, 2010
    Publication date: February 24, 2011
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • Anthranilamide inhibitors of aurora kinase
    Patent number: 7884098
    Abstract: The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; wherein R1, R1? R2, R3, R4, R5, r and s are as defined herein. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: February 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jeffrey Michael Axten, Deborah L. Bryan, David Harold Drewry, Thomas H Faitg, Timothy Francis Gallagher, Neil W Johnson, Jiri Kasparec, Jeffrey M Ralph, Domingos J. Silva
  • NOVEL COMPOUNDS
    Publication number: 20110009625
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Application
    Filed: September 16, 2010
    Publication date: January 13, 2011
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS
    Publication number: 20100311736
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.
    Type: Application
    Filed: October 22, 2008
    Publication date: December 9, 2010
    Inventors: Nicholas D. Adams, Michael Gerard Darcy, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Kenneth Allen Newlander, Xin Peng, Lance H. Ridgers